Every 8-K that Neuropace, Inc. (NPCE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NPCE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NPCE filings page.
NeuroPace, Inc. reported second-quarter 2026 results showing higher revenue and a narrowed loss while remaining unprofitable. Total revenue was $22.8 million, up 17% from $19.5 million a year earlier, driven by RNS System revenue of $22.5 million, which rose 21.3%. Non-GAAP gross margin was 83.4% and GAAP gross margin from continuing operations was 82.8%.
Non-GAAP operating expenses were $21.9 million, yielding a non-GAAP loss from operations of $2.8 million, improved from a $5.0 million loss in 2025. GAAP net loss from continuing operations was $6.2 million versus $10.0 million a year earlier. Cash, cash equivalents, short-term investments and restricted cash totaled $51.9 million as of June 30, 2026, against long-term debt of $59.0 million.
The company increased full-year 2026 guidance to total revenue of $99.5 million to $101.5 million, reflecting higher expected service revenue, and raised its non-GAAP gross margin outlook to 82.0%–83.0%. It maintained non-GAAP operating expense guidance of $90 million–$92 million and now expects Adjusted EBITDA between a loss of $7.5 million and $8.5 million.
NeuroPace, Inc. reported that the FDA informed it that the Premarket Approval Supplement seeking to expand the labeled indication for the RNS System to antiseizure medication-resistant idiopathic generalized epilepsy is not approvable in its current form and requested additional clinical evidence, including more NAUTILUS trial data and literature.
The company plans to submit a Submission Issue Request, amend its filing, and continue working with FDA on a path to approval. NAUTILUS 18‑month results showed a 77% median reduction in generalized tonic-clonic seizures and 40% seizure freedom, with strong patient and physician global improvement scores; 24‑month follow-up in a subset showed a 100% median reduction. Management reiterated that current guidance excludes any contribution from this indication and will discuss the update and full second-quarter 2026 results on an August 11, 2026 call.
NeuroPace, Inc. reported the results of its 2026 Annual Meeting of Stockholders held by live webcast on June 5, 2026. Stockholders elected Class II directors Lisa Andrade and Scott Huennekens to serve until the 2029 annual meeting and until their successors are elected and qualified.
Andrade received 15,194,450 votes for and 6,024,133 withheld, with 8,048,133 broker non-votes. Huennekens received 20,973,382 votes for and 245,201 withheld, with the same 8,048,133 broker non-votes. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,850,105 votes for, 209,301 against, and 207,310 abstentions.
NeuroPace, Inc. reported strong first quarter 2026 growth and raised its full-year revenue outlook. Non-GAAP revenue (excluding DIXI Medical) rose 20.1% to $22.0 million from $18.3 million a year earlier, driven by RNS System revenue of $21.7 million, up 19.5%.
Non-GAAP gross margin was 82.5%, while GAAP net loss was ($6.7) million. On a non-GAAP basis, loss from operations improved to ($3.3) million from ($4.1) million, and non-GAAP net loss narrowed to ($4.4) million from ($5.6) million.
For full year 2026, NeuroPace now expects revenue between $99 million and $101 million, implying 21%–23% underlying RNS growth, and reiterates non-GAAP gross margin of 81.5%–82.5% and non-GAAP operating expenses of $90–$92 million. Adjusted EBITDA is guided to a loss of ($8.5)–($9.5) million. The company completed the FDA mid-cycle review for its NAUTILUS PMA supplement and plans to report DIXI Medical as discontinued operations starting in the second quarter.
NeuroPace, Inc. reported strong growth for Q4 and full year 2025 while narrowing losses and laying out 2026 guidance. Q4 2025 revenue rose 24% to $26.6 million, driven mainly by RNS System sales of $22.4 million (up 26% year over year). Total gross margin improved to 77.4%, and RNS gross margin reached 80.5%, helping cut Q4 net loss to $2.7 million from $5.3 million a year earlier.
For 2025, revenue increased 25% to $100.0 million, with RNS System revenue of $81.7 million also up 25%. Full‑year gross margin expanded to 77.2%, and Adjusted EBITDA improved to a loss of $5.0 million. Cash, cash equivalents and short‑term investments were $61.1 million at December 31, 2025, with long‑term debt of $58.9 million.
The company plans to report DIXI Medical as discontinued operations starting in Q1 2026 and issued 2026 guidance on a continuing‑operations basis. It targets $98–$100 million in 2026 revenue, reflecting 20–22% RNS growth, non‑GAAP gross margin of 81.5–82.5%, non‑GAAP operating expenses of $90–$92 million, and Adjusted EBITDA between ($9.0) and ($10.0) million.
NeuroPace, Inc. (NPCE) reported it issued a press release announcing financial results for the fiscal quarter ended September 30, 2025. The press release, dated November 4, 2025, is furnished as Exhibit 99.1.
The company clarified the information is furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into Securities Act filings unless specifically referenced.
NeuroPace, Inc. reported that it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this current report and is incorporated by reference into the filing. The company explicitly states that the information in Item 2.02, including the exhibit, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act nor incorporated by reference in filings under the Securities Act except by specific reference. No financial figures or earnings metrics are included in the text of this report.